---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-023441"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T20:03:18.112136+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences Q3 net loss $3.4M, cash $3.8M; EB-003 advances toward IND 2026

## Summary
- Net loss of $3.4M ($10.81 per share) in Q3 2025 vs $2.1M ($43.10) in Q3 2024; cash $3.8M as of Sept 30, 2025.
- Lead candidate EB-003: completed pre-IND dose range studies, positive PTSD data, FDA pre-IND response; IND planned 2026.
- Hired Fish & Richardson to defend U.S. Patent 12,138,276 against Gilgamesh PGR; patent covers Bretisilocin (AbbVie, $1.2B).
- Completed reverse stock split 1:12 on Oct 28, 2025 after Nasdaq bid price deficiency delisting determination.
- Gross proceeds of ~$2.2M from warrant exercise; $7.9M net raised in first nine months of 2025.

## SEC filing metadata
- accession: 0001493152-25-023441
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315225023441/0001493152-25-023441-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315225023441/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-023441
- JSON: https://secwatch.observer/filing/0001493152-25-023441.json
- Plain text: https://secwatch.observer/filing/0001493152-25-023441.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.